,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2019', 'fs': 'May 2019', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CU1EH2A1'}, 'Id': 'a0POZ00000CU1EH2A1', 'Event_Date__c': '2019-05-09', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'May 2019', 'Status_History__c': 'a132P000000D5K5QAK'}, 'change': None}]",May 2019,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CU1EI2A1'}, 'Id': 'a0POZ00000CU1EI2A1', 'Event_Date__c': '2019-10-14', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2019', 'Status_History__c': 'a132P000000D6exQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>The Subcommittee recommended that pembrolizumab be funded as a bridge to transplant for the treatment for relapsed and refractory HL in individuals eligible for autologous or allogeneic stem cell transplantation who are refractory to a second or subsequent line of chemotherapy or have relapsed after at least three lines of therapy, with a medium priority.</p><p><br></p><p>The Subcommittee recommended that pembrolizumab be funded in this setting based on the high health need in a small population, the limited treatment duration and the evidence of high response rates with pembrolizumab regardless of line of therapy, which may assist in getting patients to potentially curative stem cell transplants.</p><p><br></p><p>The Subcommittee recommended the following new Special Authority criteria for the above recommended patient group:</p><p><br></p><p>Special Authority for Subsidy– PCT only – Specialist</p><p>Initial application (relapsed/refractory Hodgkin’s lymphoma) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</p><p>All of the following:</p><p>1. Either:</p><p class=""ql-indent-1"">1.1. Patient has Hodgkin lymphoma refractory to a second or subsequent line of chemotherapy; or</p><p class=""ql-indent-1"">1.2. Patient has Hodgkin lymphoma that has relapsed following three prior lines of therapy; and</p><p>2. If a sufficient response is obtained, the patient would be otherwise eligible for a planned autologous or allogeneic stem cell transplantation; and</p><p>3. Response to pembrolizumab is to be reviewed after 12 weeks (3 doses).</p><p>4. Pembrolizumab to be administered at doses no greater than 200 mg once every 3 weeks up to maximum of 18 weeks (6 doses).\xa0</p>', 'fs': '<p>The Subcommittee recommended that pembrolizumab be funded as a bridge to transplant for the treatment for relapsed and refractory HL in individuals eligible for autologous or allogeneic stem cell transplantation who are refractory to a second or subsequent line of chemotherapy or have relapsed after at least three lines of therapy, with a medium priority.</p><p><br></p><p>The Subcommittee recommended that pembrolizumab be funded in this setting based on the high health need in a small population, the limited treatment duration and the evidence of high response rates with pembrolizumab regardless of line of therapy, which may assist in getting patients to potentially curative stem cell transplants.</p><p><br></p><p>The Subcommittee recommended the following new Special Authority criteria for the above recommended patient group:</p><p><br></p><p>Special Authority for Subsidy– PCT only – Specialist</p><p>Initial application (relapsed/refractory Hodgkin’s lymphoma) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</p><p>All of the following:</p><p>1. Either:</p><p class=""ql-indent-1"">1.1. Patient has Hodgkin lymphoma refractory to a second or subsequent line of chemotherapy; or</p><p class=""ql-indent-1"">1.2. Patient has Hodgkin lymphoma that has relapsed following three prior lines of therapy; and</p><p>2. If a sufficient response is obtained, the patient would be otherwise eligible for a planned autologous or allogeneic stem cell transplantation; and</p><p>3. Response to pembrolizumab is to be reviewed after 12 weeks (3 doses).</p><p>4. Pembrolizumab to be administered at doses no greater than 200 mg once every 3 weeks up to maximum of 18 weeks (6 doses).\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p>The Subcommittee noted that in September 2018 it had considered an application for pembrolizumab for the treatment of refractory/relapsed HL after two or more lines of chemotherapy for patients who were either ineligible for, or had relapsed following, an autologous stem cell transplant. The Subcommittee recommended that the application be deferred until additional data were available.</p><p><br></p><p>The Subcommittee noted the current treatment paradigm for HL in New Zealand, where approximately 100 patients are diagnosed each year and approximately 80% are effectively cured with first line chemotherapy treatment.</p><p><br></p><p>The Subcommittee estimated that approximately 20 patients would relapse, and 16 of these would be fit enough for second-line treatment. Eight patients might be refractory to second-line therapy and would receive pembrolizumab, and eight might respond sufficiently to second-line therapy to proceed to autologous stem cell transplant. Half of those receiving pembrolizumab would respond and also get to autologous stem cell transplant. Of those 12 receiving an autologous stem cell transplant, 50% would expect to be cured but six might progress after autologous stem cell transplant and be considered for a third-line therapy.</p><p><br></p><p>Of the six patients receiving third-line chemotherapy, the Subcommittee estimated two to four patients may be treated with pembrolizumab, with a view to proceeding to allotransplant, with the remaining two responding to third-line chemotherapy and proceeding directly to allotransplant.</p><p><br></p><p>The Subcommittee noted that a maximum of 18 weeks or six doses was requested, which the Subcommittee considered appropriate.</p><p><br></p><p>The Subcommittee noted that the primary evidence for the use of pembrolizumab for the treatment of relapsed/refractory Hodgkin lymphoma comes from the previously considered single-arm, phase 2 Keynote-087 trial (Chen et al. J Clin Oncol. 2017;35:2125-32). The Subcommittee noted a high overall response rate of 57% in patients refractory to all previous lines of therapy, and 72% overall response (complete response rate 31%, partial response rate 41%) in those who hadn’t received brentuximab vedotin. The Subcommittee noted this study population aligned with the New Zealand population and was less heavily treated than the majority of patients in Keynote 87 who had been treated with brentuximab vedotin. The Subcommittee noted response rates did not vary according to the extent of previous therapy (&lt;3 vs &gt; 3 lines of therapy).</p><p><br></p><p>The Subcommittee noted auto-SCT following a response to induction therapy is strongly associated with improved survival in HL (Moskowitz et al. Blood. 2012;119:1665-70) and is thus the standard of care in NZ and internationally.</p><p><br></p><p>The Subcommittee noted a potential historical comparator could be from the CALGB 59804 trial of salvage regimens in relapsed Hodgkin’s lymphoma (Bartlett et al. Ann Oncol. 2007;18:1071-9.</p>', 'fs': '<p>The Subcommittee noted that in September 2018 it had considered an application for pembrolizumab for the treatment of refractory/relapsed HL after two or more lines of chemotherapy for patients who were either ineligible for, or had relapsed following, an autologous stem cell transplant. The Subcommittee recommended that the application be deferred until additional data were available.</p><p><br></p><p>The Subcommittee noted the current treatment paradigm for HL in New Zealand, where approximately 100 patients are diagnosed each year and approximately 80% are effectively cured with first line chemotherapy treatment.</p><p><br></p><p>The Subcommittee estimated that approximately 20 patients would relapse, and 16 of these would be fit enough for second-line treatment. Eight patients might be refractory to second-line therapy and would receive pembrolizumab, and eight might respond sufficiently to second-line therapy to proceed to autologous stem cell transplant. Half of those receiving pembrolizumab would respond and also get to autologous stem cell transplant. Of those 12 receiving an autologous stem cell transplant, 50% would expect to be cured but six might progress after autologous stem cell transplant and be considered for a third-line therapy.</p><p><br></p><p>Of the six patients receiving third-line chemotherapy, the Subcommittee estimated two to four patients may be treated with pembrolizumab, with a view to proceeding to allotransplant, with the remaining two responding to third-line chemotherapy and proceeding directly to allotransplant.</p><p><br></p><p>The Subcommittee noted that a maximum of 18 weeks or six doses was requested, which the Subcommittee considered appropriate.</p><p><br></p><p>The Subcommittee noted that the primary evidence for the use of pembrolizumab for the treatment of relapsed/refractory Hodgkin lymphoma comes from the previously considered single-arm, phase 2 Keynote-087 trial (Chen et al. J Clin Oncol. 2017;35:2125-32). The Subcommittee noted a high overall response rate of 57% in patients refractory to all previous lines of therapy, and 72% overall response (complete response rate 31%, partial response rate 41%) in those who hadn’t received brentuximab vedotin. The Subcommittee noted this study population aligned with the New Zealand population and was less heavily treated than the majority of patients in Keynote 87 who had been treated with brentuximab vedotin. The Subcommittee noted response rates did not vary according to the extent of previous therapy (&lt;3 vs &gt; 3 lines of therapy).</p><p><br></p><p>The Subcommittee noted auto-SCT following a response to induction therapy is strongly associated with improved survival in HL (Moskowitz et al. Blood. 2012;119:1665-70) and is thus the standard of care in NZ and internationally.</p><p><br></p><p>The Subcommittee noted a potential historical comparator could be from the CALGB 59804 trial of salvage regimens in relapsed Hodgkin’s lymphoma (Bartlett et al. Ann Oncol. 2007;18:1071-9.</p>', 'change': None}, 'Published_Application': {'s': '<p>The Subcommittee reviewed an application for pembrolizumab for the treatment of classical Hodgkin lymphoma (HL). The indication sought was in a narrower population than previously considered by PTAC and CaTSoP. Specifically, pembrolizumab was sought as a ‘bridge to transplant’ for the treatment for relapsed and refractory HL for individuals eligible for autologous or allogeneic stem cell transplantation, with ‘refractory or relapsed’ defined as:</p><p><br></p><p>• refractory to a second or subsequent line of chemotherapy; or </p><p>• relapsed after at least three lines of therapy.</p>', 'fs': '<p>The Subcommittee reviewed an application for pembrolizumab for the treatment of classical Hodgkin lymphoma (HL). The indication sought was in a narrower population than previously considered by PTAC and CaTSoP. Specifically, pembrolizumab was sought as a ‘bridge to transplant’ for the treatment for relapsed and refractory HL for individuals eligible for autologous or allogeneic stem cell transplantation, with ‘refractory or relapsed’ defined as:</p><p><br></p><p>• refractory to a second or subsequent line of chemotherapy; or </p><p>• relapsed after at least three lines of therapy.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf"" target=""_blank"">Cancer Subcommittee minutes</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf"" target=""_blank"">Cancer Subcommittee minutes</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CU1EJ2A1'}, 'Id': 'a0POZ00000CU1EJ2A1', 'Event_Date__c': '2019-10-18', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf"" target=""_blank"">Cancer Subcommittee minutes</a></p>', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Oct 2019', 'Published_Recommendation__c': '<p>The Subcommittee recommended that pembrolizumab be funded as a bridge to transplant for the treatment for relapsed and refractory HL in individuals eligible for autologous or allogeneic stem cell transplantation who are refractory to a second or subsequent line of chemotherapy or have relapsed after at least three lines of therapy, with a medium priority.</p><p><br></p><p>The Subcommittee recommended that pembrolizumab be funded in this setting based on the high health need in a small population, the limited treatment duration and the evidence of high response rates with pembrolizumab regardless of line of therapy, which may assist in getting patients to potentially curative stem cell transplants.</p><p><br></p><p>The Subcommittee recommended the following new Special Authority criteria for the above recommended patient group:</p><p><br></p><p>Special Authority for Subsidy– PCT only – Specialist</p><p>Initial application (relapsed/refractory Hodgkin’s lymphoma) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</p><p>All of the following:</p><p>1. Either:</p><p class=""ql-indent-1"">1.1. Patient has Hodgkin lymphoma refractory to a second or subsequent line of chemotherapy; or</p><p class=""ql-indent-1"">1.2. Patient has Hodgkin lymphoma that has relapsed following three prior lines of therapy; and</p><p>2. If a sufficient response is obtained, the patient would be otherwise eligible for a planned autologous or allogeneic stem cell transplantation; and</p><p>3. Response to pembrolizumab is to be reviewed after 12 weeks (3 doses).</p><p>4. Pembrolizumab to be administered at doses no greater than 200 mg once every 3 weeks up to maximum of 18 weeks (6 doses).\xa0</p>', 'Published_Application__c': '<p>The Subcommittee reviewed an application for pembrolizumab for the treatment of classical Hodgkin lymphoma (HL). The indication sought was in a narrower population than previously considered by PTAC and CaTSoP. Specifically, pembrolizumab was sought as a ‘bridge to transplant’ for the treatment for relapsed and refractory HL for individuals eligible for autologous or allogeneic stem cell transplantation, with ‘refractory or relapsed’ defined as:</p><p><br></p><p>• refractory to a second or subsequent line of chemotherapy; or </p><p>• relapsed after at least three lines of therapy.</p>', 'Published_Discussion__c': '<p>The Subcommittee noted that in September 2018 it had considered an application for pembrolizumab for the treatment of refractory/relapsed HL after two or more lines of chemotherapy for patients who were either ineligible for, or had relapsed following, an autologous stem cell transplant. The Subcommittee recommended that the application be deferred until additional data were available.</p><p><br></p><p>The Subcommittee noted the current treatment paradigm for HL in New Zealand, where approximately 100 patients are diagnosed each year and approximately 80% are effectively cured with first line chemotherapy treatment.</p><p><br></p><p>The Subcommittee estimated that approximately 20 patients would relapse, and 16 of these would be fit enough for second-line treatment. Eight patients might be refractory to second-line therapy and would receive pembrolizumab, and eight might respond sufficiently to second-line therapy to proceed to autologous stem cell transplant. Half of those receiving pembrolizumab would respond and also get to autologous stem cell transplant. Of those 12 receiving an autologous stem cell transplant, 50% would expect to be cured but six might progress after autologous stem cell transplant and be considered for a third-line therapy.</p><p><br></p><p>Of the six patients receiving third-line chemotherapy, the Subcommittee estimated two to four patients may be treated with pembrolizumab, with a view to proceeding to allotransplant, with the remaining two responding to third-line chemotherapy and proceeding directly to allotransplant.</p><p><br></p><p>The Subcommittee noted that a maximum of 18 weeks or six doses was requested, which the Subcommittee considered appropriate.</p><p><br></p><p>The Subcommittee noted that the primary evidence for the use of pembrolizumab for the treatment of relapsed/refractory Hodgkin lymphoma comes from the previously considered single-arm, phase 2 Keynote-087 trial (Chen et al. J Clin Oncol. 2017;35:2125-32). The Subcommittee noted a high overall response rate of 57% in patients refractory to all previous lines of therapy, and 72% overall response (complete response rate 31%, partial response rate 41%) in those who hadn’t received brentuximab vedotin. The Subcommittee noted this study population aligned with the New Zealand population and was less heavily treated than the majority of patients in Keynote 87 who had been treated with brentuximab vedotin. The Subcommittee noted response rates did not vary according to the extent of previous therapy (&lt;3 vs &gt; 3 lines of therapy).</p><p><br></p><p>The Subcommittee noted auto-SCT following a response to induction therapy is strongly associated with improved survival in HL (Moskowitz et al. Blood. 2012;119:1665-70) and is thus the standard of care in NZ and internationally.</p><p><br></p><p>The Subcommittee noted a potential historical comparator could be from the CALGB 59804 trial of salvage regimens in relapsed Hodgkin’s lymphoma (Bartlett et al. Ann Oncol. 2007;18:1071-9.</p>', 'Status_History__c': 'a132P000000D6flQAC'}, 'change': None}]",Oct 2019,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2019', 'fs': 'Nov 2019', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CU1EK2A1'}, 'Id': 'a0POZ00000CU1EK2A1', 'Event_Date__c': '2019-11-01', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Nov 2019', 'Status_History__c': 'a132P000000D85iQAC'}, 'change': None}]",Nov 2019,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CU1EL2A1'}, 'Id': 'a0POZ00000CU1EL2A1', 'Event_Date__c': '2020-09-01', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2020', 'Status_History__c': 'a132P000000DGwCQAW'}, 'change': None}]",Sep 2020,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-immunotherapy-for-six-types-of-cancer-and-treatments-to-prevent-fungal-infection"" target=""_blank"">Notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-immunotherapy-for-six-types-of-cancer-and-treatments-to-prevent-fungal-infection"" target=""_blank"">Notification</a></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2024', 'fs': 'Sep 2024', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CU1EM2A1'}, 'Id': 'a0POZ00000CU1EM2A1', 'Event_Date__c': '2024-09-12', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-immunotherapy-for-six-types-of-cancer-and-treatments-to-prevent-fungal-infection"" target=""_blank"">Notification</a></p>', 'Formatted_Date__c': 'Sep 2024', 'Status_History__c': 'a13OZ00000EAe11YAD'}, 'change': None}]",Sep 2024,False,True
